Revenue Generation - The group generated revenue of approximately RMB 7,100,000 from the sale of 5,250 cubic meters of timber during the reporting period [10]. - Ginseng sales revenue amounted to approximately RMB 16,800,000, including RMB 8,850,000 from purchased ginseng and RMB 7,950,000 from self-cultivated ginseng [12]. - The health products business recorded revenue of approximately RMB 10,500,000 during the reporting period [13]. - The company recorded revenue of approximately RMB 34,400,000 during the reporting period, an increase from RMB 31,100,000 in the previous period [16]. - Revenue for the six months ended December 31, 2025, was RMB 34,393,000, an increase of 10.3% from RMB 31,112,000 in the same period of 2024 [51]. - Total revenue for the six months ended December 31, 2025, was RMB 34,393,000, an increase from RMB 31,112,000 for the same period in 2024, representing a growth of approximately 7.3% [63]. - The revenue from the forestry business was RMB 7,068,000, while the ginseng business generated RMB 16,776,000 [69]. - For the six months ended December 31, 2024, total revenue was RMB 31,112,000, with a profit of RMB 4,978,000, indicating a year-over-year increase in revenue [71]. Profit and Expenses - Gross profit for the period was approximately RMB 4,100,000, up from RMB 2,800,000 in the prior period [17]. - Selling and distribution expenses increased to RMB 499,000 from RMB 148,000, primarily due to advertising costs [18]. - Administrative expenses decreased by approximately 9.8% to RMB 8,500,000 from RMB 9,400,000 in the previous period, mainly due to a reduction in legal and professional fees [19]. - Other income was approximately RMB 11,500,000, down from RMB 13,100,000, with net gains from changes in fair value of artificial forest assets contributing approximately RMB 7,100,000 [20]. - Financing costs increased to RMB 1,800,000 from RMB 1,300,000, attributed to interest on bills payable [21]. - The company recorded a profit of approximately RMB 5,300,000, compared to RMB 5,000,000 in the previous period, with total comprehensive income attributable to owners of RMB 5,400,000, down from RMB 6,400,000 [22]. - Profit before tax for the six months was RMB 5,256,000, slightly up from RMB 5,042,000 in the previous year [51]. - Net profit for the period was RMB 5,252,000, compared to RMB 4,978,000 in 2024, reflecting a year-on-year increase of 5.5% [51]. - Total comprehensive income for the period was RMB 5,406,000, compared to RMB 6,353,000 in 2024 [51]. Assets and Liabilities - As of December 31, 2025, the company had total assets of approximately RMB 201,300,000 and net assets of approximately RMB 56,900,000, with cash and bank balances of approximately RMB 2,600,000 [23]. - The capital debt ratio as of December 31, 2025, was approximately 71.7%, down from 77.3% as of June 30, 2025 [27]. - Non-current assets totaled RMB 160,940,000 as of December 31, 2025, compared to RMB 145,376,000 as of June 30, 2025, reflecting an increase of approximately 10.7% [52]. - Current liabilities decreased to RMB 30,075,000 as of December 31, 2025, from RMB 43,073,000 as of June 30, 2025, indicating a reduction of about 30.2% [52]. - The company's total equity increased to RMB 56,886,000 as of December 31, 2025, up from RMB 46,720,000 as of June 30, 2025, marking a growth of approximately 21.5% [53]. - The total assets as of December 31, 2025, were RMB 201,318,000, a slight decrease from RMB 205,417,000 as of June 30, 2025 [72]. - The total liabilities decreased from RMB 158,697,000 as of June 30, 2025, to RMB 144,432,000 as of December 31, 2025 [72]. Share Capital and Financing - The company announced a placement of up to 17,000,000 new shares at a price of HKD 0.28 per share, aiming to raise approximately HKD 4,630,000 for general working capital [33]. - The company has issued and paid-up ordinary shares totaling 102,924,000 shares, with a par value of HKD 0.1 per share [98]. - The company underwent a share restructuring, resulting in a reduction of 9,000,000 shares on July 1, 2025 [98]. - The company raised HKD 1,700,000 through the placement of new shares during the reporting period [98]. - The book value of the issued shares as of December 31, 2025, is RMB 9,406,000 [98]. Ginseng and Health Products - The group has initiated ginseng cultivation on its forest land, with the first phase involving the planting of approximately 6 million ginseng plants [11]. - The group plans to gradually reduce reliance on suppliers for aged ginseng as it builds sufficient inventory of its own [14]. - The group has established a long-term supply framework agreement with suppliers to ensure a stable supply of aged ginseng [12]. - The group aims to expand its health products market into China in the future [14]. - The group has expanded its business into health product manufacturing and trade, opening a 150 square meter store in Hong Kong [13]. Environmental and Regulatory Risks - The group faces regulatory and environmental risks and has established environmental policies to comply with local laws [89]. - The group's revenue depends on sufficient timber harvesting capacity, which may be affected by climate and natural disasters [90]. - The group must contend with risks related to fluctuations in timber prices and sales volumes, with management conducting regular industry trend analyses to control this risk [91]. Inventory and Receivables - As of December 31, 2025, trade receivables amounted to RMB 24,442,000, a decrease of approximately 27.8% from RMB 33,796,000 as of June 30, 2025 [93]. - As of December 31, 2025, trade payables were RMB 2,493,000, down approximately 55.1% from RMB 5,535,000 as of June 30, 2025 [94]. - The inventory increased significantly to RMB 5,987,000 as of December 31, 2025, from RMB 1,480,000 as of June 30, 2025, representing a growth of approximately 303.4% [52].
中国健康科技集团(01069) - 2026 - 中期财报